Empyema Treated With tPA & DNAse

Children's Mercy Hospital Kansas City

Overview

The objective of this study is to scientifically evaluate a new substrate for fibrinolysis compared to our standard tPA. The hypothesis, driven by a recent prospective trial, is that tPA may benefit from the addition of DNAse. The primary outcome variable between the two techniques will be length of hospitalization after initiation of treatment.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Conditions

Empyema

Interventions

tPA aloneBIOLOGICAL

tPA plus dornaseBIOLOGICAL

Eligibility

Sex: ALLMax age: 17 Years

Medical Language ↔ Plain English

Inclusion Criteria: Patients less than 18 years of age requiring an intervention for empyema by one of the following: * Septation or loculation seen on ultrasound or computed tomography or * Greater than 10,000 white blood cells identified on pleural tap Exclusion Criteria: * Immunodeficiency process * Secondary diagnosis or condition that will keep them in the hospital beyond the empyema * Existing contraindications to chest tube * Documented allergy to one of the study medications

Locations (1)

Children's Mercy Hospital

Kansas City, Missouri, United States

Outcomes

Primary Outcomes

Length of stay

Time frame: 3 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.